目的 探討天麥消渴片聯(lián)合西格列汀治療肥胖型2型糖尿病的臨床效果。方法 選取滎陽市人民醫(yī)院2015年1月-2017年1月收治的肥胖2型糖尿病患者116例，隨機分成對照組和治療組，每組各58例。對照組患者口服磷酸西格列汀片，1片/次，1次/d。治療組在對照組的基礎(chǔ)上口服天麥消渴片，2片/次，2次/d。所有患者均治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者糖尿病相關(guān)指標、炎性指標和不良反應情況。結(jié)果 治療后，對照組和治療組臨床總有效率分別為81.03%、96.55%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者體質(zhì)量指數(shù)（BMI）、空腹血糖（FBG）、糖化血紅蛋白（HbA1c）均顯著性降低，穩(wěn)態(tài)模型胰島素分泌指數(shù)（HOMA-β）顯著升高，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組這些指標的改善情況均要優(yōu)于對照組患者，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者C反應蛋白（CRP）、內(nèi)皮素-1（ET-1）、血栓素A2（TXA2）、NO、IL-6水平均明顯降低（P<0.05）；且治療組患者各項炎性指標均要明顯低于對照組（P<0.05）。結(jié)論 天麥消渴片聯(lián)合西格列汀治療肥胖2型糖尿病療效顯著，安全可靠，具有一定的臨床推廣應用價值。

Objective To explore the clinical effect of Tianmai Xiaoke Tablets combined with sitagliptin in treatment of obesity type 2 diabetes. Methods Patients (116 cases) with obesity type 2 diabetes in Xingyang People's Hospital from January 2015 to January 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were po administered with Sitagliptin Phosphate Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Tianmai Xiaoke Tablets on the basis of the control group, 2 tablets/time, twice daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, the diabetes related indicators, inflammatory markers and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.03% and 96.55%, respectively, and there were differences between two groups (P<0.05). After treatment, the BMI, FBG and HbA1c in two groups was significantly decreased, but HOMA-β was significantly increased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the CRP, ET-1, TXA2, NO, IL-6 levels in two groups were significantly decreased, and there were differences in the same group (P<0.05). And the inflammatory markers levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Tianmai Xiaoke Tablets combined with sitagliptin has significant effect in treatment of obesity type 2 diabetes with high safety, which has a certain clinical application value.